Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer

Sensitizing mutations in the epidermal growth factor receptor (EGFR) predict response to EGFR tyrosine kinase inhibitors (TKIs) and both first- and second-generation TKIs are available as first-line treatment options in patients with advanced EGFR-mutant non-small cell lung cancer. Eventual resistan...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Front Oncol
Prif Awduron: Barnes, Tristan A., O’Kane, Grainne M., Vincent, Mark David, Leighl, Natasha B.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Frontiers Media S.A. 2017
Pynciau:
Oncology
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5449484/
https://ncbi.nlm.nih.gov/pubmed/28620581
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2017.00113
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg